clinical trial · NCT06043700
A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology
Alzheimer's DiseaseNo Intervention
brief summary
The primary purpose of this study is to identify participants with or without symptoms of Alzheimer's Disease (AD) that are at high risk for brain amyloid pathology using blood-based biomarkers.
started
Sep 12, 2023
primary completion
Mar 31, 2028
completion
Mar 31, 2028
last updated
Mar 5, 2026
official title
A Community-Based Screening Program to Identify, Using Blood-Based Biomarkers, Individuals With or Without Alzheimer's Disease Symptoms Who Are at High Risk for Brain Amyloid Pathology
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol